June 28, 2024 12:37 PM EDTUpdated 02:11 PM
Deals
Pharma
Manufacturing

Rovi teas­es ac­qui­si­tion of­fers for its CD­MO unit po­ten­tial­ly worth €2B to €3B

Ayisha Sharma

News Reporter

Rovi has at­tract­ed mul­ti­ple buy­out bids for its con­tract man­u­fac­tur­ing busi­ness af­ter the com­pa­ny said it was weigh­ing its op­tions for the di­vi­sion sev­er­al months …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

In­side BAR­DA's multi­bil­lion-dol­lar ef­fort to fund long-shot biotechs for Covid

Bio­gen is pur­su­ing more deal­mak­ing this year, with plans to spend up to $8B

A service from the Financial Times